NASDAQ
ALT

Altimmune Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Altimmune Inc Stock Price

Vitals

Today's Low:
$2.43
Today's High:
$2.64
Open Price:
$2.45
52W Low:
$3.83
52W High:
$23.49
Prev. Close:
$2.43
Volume:
1443090

Company Statistics

Market Cap.:
$544.53 million
Book Value:
3.767
Revenue TTM:
$-68000
Operating Margin TTM:
128902.94%
Gross Profit TTM:
$-70520000
Profit Margin:
0%
Return on Assets TTM:
-25.73%
Return on Equity TTM:
-44.07%

Company Profile

Altimmune Inc had its IPO on 2005-10-06 under the ticker symbol ALT.

The company operates in the Healthcare sector and Biotechnology industry. Altimmune Inc has a staff strength of 52 employees.

Stock update

Shares of Altimmune Inc opened at $2.45 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.43 - $2.64, and closed at $2.61.

This is a +7.41% increase from the previous day's closing price.

A total volume of 1,443,090 shares were traded at the close of the day’s session.

In the last one week, shares of Altimmune Inc have slipped by -1.51%.

Altimmune Inc's Key Ratios

Altimmune Inc has a market cap of $544.53 million, indicating a price to book ratio of 2.5847 and a price to sales ratio of 162.9822.

In the last 12-months Altimmune Inc’s revenue was $-68000 with a gross profit of $-70520000 and an EBITDA of $-87612664. The EBITDA ratio measures Altimmune Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Altimmune Inc’s operating margin was 128902.94% while its return on assets stood at -25.73% with a return of equity of -44.07%.

In Q4, Altimmune Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 98.7%.

Altimmune Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.75 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Altimmune Inc’s profitability.

Altimmune Inc stock is trading at a EV to sales ratio of 99.2173 and a EV to EBITDA ratio of -3.7915. Its price to sales ratio in the trailing 12-months stood at 162.9822.

Altimmune Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$206.93 million
Total Liabilities
$17.05 million
Operating Cash Flow
$0
Capital Expenditure
$38000
Dividend Payout Ratio
0%

Altimmune Inc ended 2024 with $206.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $206.93 million while shareholder equity stood at $185.29 million.

Altimmune Inc ended 2024 with $0 in deferred long-term liabilities, $17.05 million in other current liabilities, in common stock, $-377884000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $111.10 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

Altimmune Inc’s total current assets stands at $192.81 million while long-term investments were $0 and short-term investments were $73.78 million. Its net receivables were $173000.00 compared to accounts payable of $4.80 million and inventory worth $0.

In 2024, Altimmune Inc's operating cash flow was $0 while its capital expenditure stood at $38000.

Comparatively, Altimmune Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.61
52-Week High
$23.49
52-Week Low
$3.83
Analyst Target Price
$29.38

Altimmune Inc stock is currently trading at $2.61 per share. It touched a 52-week high of $23.49 and a 52-week low of $23.49. Analysts tracking the stock have a 12-month average target price of $29.38.

Its 50-day moving average was $2.93 and 200-day moving average was $7.33 The short ratio stood at 4.78 indicating a short percent outstanding of 0%.

Around 81.4% of the company’s stock are held by insiders while 9414.2% are held by institutions.

Frequently Asked Questions About Altimmune Inc

The stock symbol (also called stock or share ticker) of Altimmune Inc is ALT

The IPO of Altimmune Inc took place on 2005-10-06

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$1.6
-0.05
-3.03%
$24.96
-0.08
-0.32%
$0.44
-0
-0.23%
$32.87
-0.61
-1.82%
$67.54
-1.46
-2.12%
$0.12
-0
-1.67%
$22.4
0.45
+2.05%
$1.56
0.08
+5.41%
$0.29
0.04
+15.73%
$14.5
-0.5
-3.33%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Address

910 Clopper Road, Gaithersburg, MD, United States, 20878